Sep 28, 2020

Highp brings video and interactivity to Veeva Approved Email

Highp announces a major new update featuring Veeva Approved Email integration

article header

Highp for Veeva Approved Email. New email template with dynamic link to Highp message.

Warsaw, Poland - Highp for Veeva Approved Email enables Veeva CRM customers to enhance email communication in a more interactive format and video content. 

Highp offers a complete solution and guidelines to design and deliver new push-video services. 

Marketers can now extend email campaigns to the new, more meaningful, and convincing services, with personal field force video invitations, interactivity, rich-video-content, and frictionless customer experience on any device. As a result, pharmaceutical companies improve access to HCPs, increase SOV and NPS.

- Finally, your representative can send Highp message using Veeva Approved Email. 
Igor Gnot, CEO, Connectmedica

Highp for Veeva Approved Email

For more information

Visit and follow us on the Highp showcase page at Linkedin for more up-to-date news. https://www.linkedin.com/showcase/highp

Watch Highp for Approved Email demo on Vimeo https://vimeo.com/462352593 or LinkedIn   

 

Connect with our sales team:

World wide: Pawel Mazur,

Italy: Francesca Carnevale Pellino

APAC, MENA, France: Quentin Dutartre

Iberia / LATAM: Pedro Bandeira

Poland: Anna SmoleńAnna MurawskaMarcel Lewandowicz

Strategic customers: BMS, AstraZeneca, Novartis, Pfizer, Abbott: Michal Komorniczak

 

Backgrounder:

Veeva is a leading CRM provider for pharmaceutical companies.
The list of Veeva customers includes Actelion, GSK, Astellas, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Teva, Coloplast, Daiichi-Sankyo, Lilly, Ipsen, Leo, Merck, Nestle, Novartis, Takeda, Vertex. 

Highp is a new digital solution for accessing healthcare professionals developed by Connectmedica.
Available worldwide in over 40 markets. The list of Highp customers includes Roche, BMS, Abbott, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Teva, Daiichi-Sankyo, Ipsen, Leo, Novartis, and Vertex.